|
**Overview**: AML MRD Monitoring Panel**Introduction**: The AML MRD Monitoring Panel is a diagnostic tool designed to monitor acute myeloid leukemia residual disease using whole blood or bone marrow samples. In India, AML has ~2-3 per 100,000 incidence, with MRD positivity post-induction predicting relapse (~60-80 percent risk if positive). High morbidity from under-monitoring in rural/low-SES patients post-chemotherapy, limited molecular/flow labs, delayed intensified therapy or HSCT leading to relapse or mortality. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs PCR for AML-specific markers (NPM1, FLT3, CBFB-MYH11, RUNX1-RUNX1T1, etc.) and MRD quantification over 1-2 days with high sensitivity (10^-4 to 10^-5), valuable for post-treatment surveillance. This diagnostic falls under leukemia monitoring and targets AML patients in remission, addressing accurate detection to guide maintenance therapy or transplant. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise MRD assessment and improving relapse-free survival. Its blood/bone marrow-based approach ensures reliable quantification.**Other Names**: AML MRD Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology, compliant with 2025 standards.**Historical Milestone**: MRD PCR standard in AML since 2010s; in India, expanding in tertiary centers.**Purpose**: The test assesses 2 parameters including AML-specific markers to guide MRD monitoring, detect residual disease, inform therapy escalation.**Test Parameters**: 1. AML-Specific Markers, 2. MRD Quantification.**Pretest Condition**: No fasting required; patients should be AML in remission.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on treatment phase, prior MRD.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected MRD including relapse, benefits of monitoring, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and quantify MRD within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low disease burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Detectable MRD indicates high relapse risk, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Flow cytometry MRD, NGS for confirmation.**Test Limitations**: Marker-specific; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Leukemia Studies India 2023. |
